IE
ANEB

Israel Englander’s Anebulo Pharmaceuticals ANEB Stock Holding History

Israel Englander’s Portfolio ANEB Stock Details ANEB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-153,809
Closed -$221K – 5995
2025
Q2 		$221K Sell
153,809
-5,158
-3% -$5.88K ﹤0.01% 5319
2025
Q1 		$207K Buy
+158,967
New +$234K ﹤0.01% 5293

Other funds holding ANEB

2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Israel Englander's ANEB Position: Q3 2025 in Review

Israel Englander sold out of Anebulo Pharmaceuticals (ANEB) in Q3 2025, closing a stake of 153,809 shares — an estimated $221K sold.

Israel Englander first reported a position in ANEB in Q1 2025 and held it in 2 quarters. The position peaked at $221K in Q2 2025. 21 funds tracked by Wall St. Rank hold ANEB as of Q3 2025.

  • Israel Englander reported no remaining Anebulo Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Israel Englander sold 153,809 Anebulo Pharmaceuticals shares in Q3 2025, an estimated $221K.
  • Israel Englander first reported a position in Anebulo Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Israel Englander's Anebulo Pharmaceuticals position peaked at $221K in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.